Ob/Gyn Articles

Ob/Gyn

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pickar JH et al. – When combined with CE (0.625 mg or 0.45 mg), BZA (20 mg) was the lowest effective dose that prevented endometrial hyperplasia over 2 years of study, creating the possibility for a new, progestin–free menopausal therapy.


Today in Clinical Pharmacology...keeping you current

A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09

Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09

Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09

Today in Gynecologic Oncology...keeping you current

Ovarian cancer screening and early detection
Women's Health, 11/03/09

Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09

Use of Fertility Drugs and Risk of Uterine Cancer: Results From a Large Danish Population-based Cohort Study
American Journal of Epidemiology, 11/04/09

Today in Menopausal Medicine...keeping you current

A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09

Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
Clinical Interventions in Aging, 11/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address